S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
S&P 500   4,050.83 (+0.57%)
DOW   32,859.03 (+0.43%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:AXNX

Axonics - AXNX Stock Forecast, Price & News

$54.41
-1.60 (-2.86%)
(As of 03/30/2023 05:11 PM ET)
Add
Compare
Today's Range
$54.01
$57.01
50-Day Range
$52.60
$62.66
52-Week Range
$38.41
$79.92
Volume
739,110 shs
Average Volume
694,362 shs
Market Capitalization
$2.72 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.00

Axonics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.88 Rating Score
Upside/​Downside
45.2% Upside
$79.00 Price Target
Short Interest
Bearish
7.67% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
0.43mentions of Axonics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$11.94 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.58) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

315th out of 1,009 stocks

Surgical & Medical Instruments Industry

28th out of 103 stocks


AXNX stock logo

About Axonics (NASDAQ:AXNX) Stock

Axonics, Inc. is a medical device company, which engages in developing and commercializing of novel implantable sacral neuromodulation (SNM) devices to treat patients with bladder and bowel dysfunction. Its product Bulkamid, which is a urethral bulking agent used to treat stress urinary incontinence in women. The company was founded by Raymond W. Cohen, Guang Qiang Jiang, and Danny L. Dearen in March 2012 and is headquartered in Irvine, CA.

Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Fed's Shocking New Plan to Control Your Money
The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 
When Will Axonics, Inc. (NASDAQ:AXNX) Breakeven?
Should You Invest in Axonics (AXNX)?
Should You Invest in Axonics (AXNX)?
Why Axonics (AXNX) Surged in the Third Quarter?
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

AXNX Company Calendar

Last Earnings
3/01/2023
Today
3/30/2023
Next Earnings (Estimated)
5/04/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AXNX
Employees
517
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$69.00
Forecasted Upside/Downside
+41.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.88
Research Coverage
8 Analysts

Profitability

Net Income
$-59,700,000.00
Pretax Margin
-22.77%

Debt

Sales & Book Value

Annual Sales
$273.70 million
Book Value
$11.51 per share

Miscellaneous

Free Float
48,810,000
Market Cap
$2.80 billion
Optionable
Not Optionable
Beta
0.41

Key Executives

  • Raymond Wayne CohenRaymond Wayne Cohen
    Chief Executive Officer & Director
  • Danny L. DearenDanny L. Dearen
    President & Chief Financial Officer
  • Rinda K. SamaRinda K. Sama
    Chief Operating Officer
  • Guang Qiang Jiang
    Chief Technology Officer
  • Karen NoblettKaren Noblett
    Chief Medical Officer













AXNX Stock - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXNX shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price forecast for 2023?

8 Wall Street analysts have issued 1 year target prices for Axonics' stock. Their AXNX share price forecasts range from $69.00 to $90.00. On average, they anticipate the company's stock price to reach $79.00 in the next year. This suggests a possible upside of 41.0% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2023?

Axonics' stock was trading at $62.53 on January 1st, 2023. Since then, AXNX shares have decreased by 10.4% and is now trading at $56.01.
View the best growth stocks for 2023 here
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings results on Wednesday, March, 1st. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.24. The firm had revenue of $85.90 million for the quarter, compared to the consensus estimate of $84.14 million. Axonics had a negative trailing twelve-month return on equity of 11.82% and a negative net margin of 21.81%. Axonics's revenue for the quarter was up 61.6% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.34) earnings per share.

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its FY 2023 earnings guidance on Thursday, March, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $342.00 million-$342.00 million, compared to the consensus revenue estimate of $336.36 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include Raytheon Technologies (RTX), Honeywell International (HON), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

(AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

What is Axonics' stock symbol?

Axonics trades on the NASDAQ under the ticker symbol "AXNX."

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of institutional and retail investors. Top institutional investors include Bamco Inc. NY (3.58%), Lord Abbett & CO. LLC (3.37%), Norges Bank (2.47%), Credit Suisse AG (1.94%), Fred Alger Management LLC (1.86%) and Geode Capital Management LLC (1.85%). Insiders that own company stock include Alfred J Ford Jr, Alfred J Ford, Jr, Bakker Juliet Tammenoms, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Raymond W Cohen, Raymond W Cohen, Rinda Sama and Robert E Mcnamara.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Axonics' stock price today?

One share of AXNX stock can currently be purchased for approximately $56.01.

How much money does Axonics make?

Axonics (NASDAQ:AXNX) has a market capitalization of $2.80 billion and generates $273.70 million in revenue each year. The company earns $-59,700,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

How many employees does Axonics have?

The company employs 517 workers across the globe.

How can I contact Axonics?

Axonics' mailing address is 26 TECHNOLOGY DRIVE, IRVINE CA, 92618. The official website for the company is www.axonics.com. The company can be reached via phone at (949) 396-6322, via email at ir@axonics.com, or via fax at 949-396-6321.

This page (NASDAQ:AXNX) was last updated on 3/30/2023 by MarketBeat.com Staff